Who are Phase B: Triplixam / Elestar HCT's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phase-b-triplixam-elestar-hct.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Phase B: Triplixam / Elestar HCT — Competitive Intelligence Brief

Phase B: Triplixam / Elestar HCT (Phase B: Triplixam / Elestar HCT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fixed-dose combination antihypertensive (calcium channel blocker + ARB + thiazide diuretic). Area: Cardiovascular.

marketed Fixed-dose combination antihypertensive (calcium channel blocker + ARB + thiazide diuretic) L-type calcium channels, angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Phase B: Triplixam / Elestar HCT (Phase B: Triplixam / Elestar HCT) — National Institute of Cardiology, Warsaw, Poland. Triplixam/Elestar HCT is a fixed-dose combination that lowers blood pressure through multiple mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuretic action.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Phase B: Triplixam / Elestar HCT TARGET	Phase B: Triplixam / Elestar HCT	National Institute of Cardiology, Warsaw, Poland	marketed	Fixed-dose combination antihypertensive (calcium channel blocker + ARB + thiazide diuretic)	L-type calcium channels, angiotensin II type 1 receptor (AT1R), sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fixed-dose combination antihypertensive (calcium channel blocker + ARB + thiazide diuretic) class)

National Institute of Cardiology, Warsaw, Poland · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Phase B: Triplixam / Elestar HCT — Competitive Intelligence Brief. https://druglandscape.com/ci/phase-b-triplixam-elestar-hct. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab